Max Rosett sold $1.4M of IMNM
Chief Financial Officer at Immunome Inc.. 65,000 shares at an average of $21.92, traded Apr 2, 2026, filed Apr 3, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 55% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.8%, 3m +9.9%, 6m -2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001994071-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | MOption exercise Common Stock10b5-1 | +31,848 | $1.05 | $33k | 79,324 | Apr 3, 2026 |
| Apr 2, 2026 | MOption exercise Common Stock10b5-1 | +39,713 | $1.35 | $54k | 119,037 | Apr 3, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -63,656 | $21.91 | $1.4M | 55,381 | Apr 3, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,344 | $22.48 | $30k | 54,037 | Apr 3, 2026 |
| Apr 2, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | -31,848 | $0.00 | $0 | 60,000 | Apr 3, 2026 |
| Apr 2, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | -39,713 | $0.00 | $0 | 0 | Apr 3, 2026 |
Related signals
Other insiders at Immunome Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Immunome Inc. | Jack Higgins Chief Scientific Officer | $334k 13,200 shares | -17% | |
| 48Moderate | Immunome Inc. | Isaac Barchas director | $2.2M 83,464 shares | -115% | |
| 37Weak | Immunome Inc. | Isaac Barchas director | $940k 36,088 shares | -33% | |
| 33Weak | Immunome Inc. | Kinney Horn CHIEF BUSINESS OFFICER | $2.3M 90,616 shares | -100% | |
| 20Weak | Immunome Inc. | Kinney Horn CHIEF BUSINESS OFFICER | $27k 1,092 shares | -100% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $2.4M 100,000 shares | -48% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.2M 55,000 shares | -78% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $4.4M 201,050 shares | -49% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.1M 55,000 shares | -78% | |
| 47Moderate | Immunome Inc. | Max Rosett Chief Financial Officer | $1.1M 60,000 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.